NEW YORK (GenomeWeb) – As part of its overall strategy for sustained growth, Thermo Fisher Scientific has been developing a number of new clinical research and diagnostic products, ranging from US Food and Drug Administration-cleared immunoassays to next-generation sequencing-based panels, and is partnering with others to develop molecular diagnostic kits.

In a conference call yesterday to discuss the company's third quarter earnings, CEO Marc Casper highlighted several of the firm's recent initiatives and product launches in the clinical arena.